Počet záznamů: 1  

Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy

  1. 1.
    0574383 - ÚOCHB 2024 RIV NL eng J - Článek v odborném periodiku
    Dejmek, Milan - Brázdová, Andrea - Otava, Tomáš - Pimková Polidarová, Markéta - Klíma, Martin - Smola, Miroslav - Vavřina, Zdeněk - Buděšínský, Miloš - Dračínský, Martin - Liboska, Radek - Bouřa, Evžen - Birkuš, Gabriel - Nencka, Radim
    Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
    European Journal of Medicinal Chemistry. Roč. 259, November (2023), č. článku 115685. ISSN 0223-5234. E-ISSN 1768-3254
    Grant CEP: GA MŠMT(CZ) LX22NPO5103; GA MZd(CZ) NU20-05-00472
    Výzkumná infrastruktura: CCP II - 90126
    Institucionální podpora: RVO:61388963
    Klíčová slova: cyclic dinucleotides * STING * cancer * intratumoral administration * immunotherapy
    Obor OECD: Medicinal chemistry
    Impakt faktor: 6.7, rok: 2022
    Způsob publikování: Open access
    https://doi.org/10.1016/j.ejmech.2023.115685

    Cyclic dinucleotides (CDNs) trigger the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, which plays a key role in cytosolic DNA sensing and thus in immunomodulation against infections, cell damage and cancer. However, cancer immunotherapy trials with CDNs have shown immune activation, but not complete tumor regression. Nevertheless, we designed a novel class of CDNs containing vinylphosphonate based on a STING-affinity screening assay. In vitro, acyloxymethyl phosphate/phosphonate prodrugs of these vinylphosphonate CDNs were up to 1000-fold more potent than the clinical candidate ADU-S100. In vivo, the lead prodrug induced tumor-specific T cell priming and facilitated tumor regression in the 4T1 syngeneic mouse model of breast cancer. Moreover, we solved the crystal structure of this ligand bound to the STING protein. Therefore, our findings not only validate the therapeutic potential of vinylphosphonate CDNs but also open up opportunities for drug development in cancer immunotherapy bridging innate and adaptive immunity.
    Trvalý link: https://hdl.handle.net/11104/0344716


    Vědecká data: PDB
     
    Název souboruStaženoVelikostKomentářVerzePřístup
    10.1016j.ejmech.2023.115685.pdf05.2 MBVydavatelský postprintpovolen
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.